Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/5/2018
SIETES contiene 92347 citas

 
 
 1 a 20 de 160 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
3. Cita con resumen
Casassus B. Europe urged to take action on drug shortages. Lancet 2015;385:1279-80. [Ref.ID 99016]
4. Cita con resumen
Anónimo. Drug manufacturers race to cure Ebola. DIA Daily 2014:20 de octubre. [Ref.ID 98121]
5. Cita con resumen
Laurance J. Genzyme restores some access to MS drug after neurologists protest. BMJ 2013;346:1. [Ref.ID 94921]
6. Cita con resumen
Thompson AJ, Giovannoni G. Removal of alemtuzumab for patients with aggressive MS. BMJ 2013;346:10. [Ref.ID 94828]
7.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
8.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
9.Tiene citas relacionadas
Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]
10.Tiene citas relacionadas Cita con resumen
Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]
11. Cita con resumen
Laurance J. Neurologists appeal to health secretary over withdrawal of drug. BMJ 2012;345:2. [Ref.ID 94035]
12. Cita con resumen
Chabner BA. Drug shortages - A critical challenge for the generic-drug market. N Engl J Med 2011;365:2147-9. [Ref.ID 91926]
13. Cita con resumen
McGirk J. Norway investigates Gaza's drug crisis. Lancet 2011;377:1225-6. [Ref.ID 90367]
14. Cita con resumen
15. Cita con resumen
Lee K, Harmer A. Ten years of the Global Alliance for Vaccines and Immunisation. BMJ 2010;341:58-9. [Ref.ID 88868]
16. Cita con resumen
Mayor S. DH agrees deal with GSK on vaccine. BMJ 2010;340:830. [Ref.ID 88338]
17.Tiene citas relacionadas Cita con resumen
Hull S, Boomla K. Vitamin D deficiency. New preparations needed. BMJ 2010;340:380. [Ref.ID 87881]
18.Tiene citas relacionadas Cita con resumen
Da Costa AJ. Vitamin D deficiency. How can we treat it in the UK?. BMJ 2010;340:379-80. [Ref.ID 87880]
19. Cita con resumen
Anónimo. Supply and safety issues surrounding an H1N1 vaccine. Lancet 2009;374:358. [Ref.ID 86401]
20. Cita con resumen
Navario P. PEPFAR's biggest success is also its largest liability. Lancet 2009;374:184-5. [Ref.ID 86318]
Seleccionar todas
 
 1 a 20 de 160 siguiente >>